|
|
Volumn 55, Issue 4-5, 2011, Pages 395-398
|
|
Anti-angiogenesis in cancer; met and unmet goals -an interview with robert kerbel
|
|
Author keywords
Anti VEGF; Metronomic chemotherapy; TKI; Vasculogenesis; VEGF
|
|
Indexed keywords
BEVACIZUMAB;
PROTEIN TYROSINE KINASE INHIBITOR;
SORAFENIB;
SUNITINIB;
VASCULOTROPIN;
ANTIANGIOGENIC THERAPY;
ARTICLE;
BREAST CANCER;
CANCER ADJUVANT THERAPY;
CELL SURVIVAL;
COLORECTAL CANCER;
DRUG MECHANISM;
DRUG RESISTANCE;
DRUG TARGETING;
ENDOTHELIUM CELL;
GENE MUTATION;
HUMAN;
MAINTENANCE THERAPY;
MOLECULARLY TARGETED THERAPY;
NONHUMAN;
PRIORITY JOURNAL;
TUMOR CELL;
TUMOR VASCULARIZATION;
ANGIOGENESIS INHIBITORS;
ANIMALS;
HISTORY, 20TH CENTURY;
HISTORY, 21ST CENTURY;
HUMANS;
NEOPLASMS;
NEOVASCULARIZATION, PATHOLOGIC;
ONTARIO;
RESEARCH;
VASCULAR ENDOTHELIAL GROWTH FACTOR A;
|
|
EID: 79960999672
PISSN: 02146282
EISSN: None
Source Type: Journal
DOI: 10.1387/ijdb.103217fb Document Type: Article |
|
Times cited : (4)
|
|
References (0)
|
